A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

HIV Infections Clinical Trial

Official title:

An Exploratory Study of the Antiretroviral Activity of 1592U89 When Administered in Combination With Other Specific Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in NRTI Experienced Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002364
• Other study ID #: 238C
• Secondary ID: CNAA 2003
• Status: Completed
• Phase: Phase 2
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: April 1997
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of 1592U89 when administered in combination with specific marketed NRTIs.

Description:

Patients will all receive oral doses of 1592U89 in combination with protocol specific current antiretroviral therapy. The treatment groups will be assigned based on each subject's previous NRTI experience.

The study medication is self administered and all evaluations will be performed on an outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria

Patients must have:

• CD4+ cell count >= 100 /mm3.

• Plasma HIV RNA >= 30,000 copies/ml.

• Study participants may be recruited from all clinical categories, provided they do not meet any of the exclusion criteria.

• Parent or legal guardian to sign written, informed consent for patients under the age of 18.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

• Patients with active or ongoing AIDS-defining opportunistic infection or disease. NOTE:

• For this study, a CD4+ cell count <= 200 cells/mm3 in the absence of any other AIDS defining indicator condition is not considered an AIDS defining event.

• Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption.

• Patients with life threatening infection or other serious medical conditions whose participation may compromise patient safety.

Concurrent Medication:

Excluded:

• Treatment with cytotoxic chemotherapeutic agents within the 24 weeks of the study.

• Patients receiving other investigational drugs.

• Foscarnet therapy or therapy with other agents with documented activity against HIV in vitro.

• Treatment with immunomodulators.

• Patients on methadone.

Concurrent Treatment:

Excluded:

• Treatment with radiation therapy within the 24 weeks of the study. NOTE:

• Localized radiation therapy may be permitted following consultation with the sponsor.

Patients with any of the following prior conditions are excluded:

• Subjects with a history of lymphoma.

• Subjects with a history of clinically apparent pancreatitis or hepatitis within the last 6 months.

Prior Medication:

Excluded:

• Treatment with any antiretroviral therapy with NRTIs (alone or in combination) other than those defined for each treatment group.

• Treatment with any non-nucleoside RT inhibitors or protease inhibitors.

• Treatment with cytotoxic chemotherapeutic agents within 1 month prior to study entry.

• Investigational HIV vaccine within the past 3 months.

• Immunomodulating agents such as systematic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry.

Prior Treatment:

Excluded:

• Treatment with radiation therapy within 1 month of entry.

Risk Behavior:

Excluded:

Patients with current alcohol or illicit drug use that, in the opinion of the principal investigator, may interfere with the patient's ability to comply with the study protocol.

Study Design

Endpoint Classification: Safety Study, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Abacavir sulfate

Locations

Country	Name	City	State
United States	IDC Research Initiative	Altamonte Springs	Florida
United States	AIDS Research Consortium of Atlanta	Atlanta	Georgia
United States	North Broward Hosp District	Fort Lauderdale	Florida
United States	Marin County Specialty Clinic	Greenbrae	California
United States	Univ of Kentucky Med Ctr	Lexington	Kentucky
United States	Kraus Med Partners	Los Angeles	California
United States	Beth Israel Med Ctr	New York	New York
United States	ViRx Inc	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Glaxo Wellcome

Country where clinical trial is conducted

United States,